| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 530388200 | Binds microorganism or normal or mutant component or product thereof (e.g., animal cell, cell-surface antigen, secretory product, etc.) | 50 |
| 20110054149 | NOGO-A Neutralizing Immunoglobulins for the Treatment of Neurological Diseases - The present invention relates to antibodies to NOGO, pharmaceutical formulations containing them and to the use of such antibodies in the treatment and/or prophylaxis of neurological diseases/disorders. | 03-03-2011 |
| 20110275789 | Methods and Kits for Detection of Thromboxane A2 Metabolites - Methods, compositions and kits are provided for measuring aspirin's anti-thrombotic effectiveness on a subject. Included are a novel assay for quickly and specifically measuring TxA2 metabolite levels in urine and correlating the levels with aspirin dose in a subject. The methods, compositions and kits utilize a novel anti TxA2 metabolite antibody. | 11-10-2011 |
| 20120108795 | Antibodies Binding Human Collagen II - The present invention relates to antibodies against human collagen II, polypeptides and polynucleotides encoding human collagen II antibodies or fragments thereof, and methods of making and using the foregoing. | 05-03-2012 |
| 20130274449 | Anti-CD100 Neutralizing Antibodies and Methods of Using the Same - Compositions and methods are provided for treating diseases associated with CD100, including certain autoimmune diseases, inflammatory diseases, and cancers. In particular, anti-CD100 monoclonal antibodies have been developed to neutralize CD100. | 10-17-2013 |
| 20140249298 | ANTI-HUMAN EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1 (hENT1) ANTIBODIES ADN METHODS OF USE THEREOF - This invention provides monoclonal antibodies that recognize hENT1. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and/or prophylactic in disorders associated with aberrant hENT1 expression and/or activity. | 09-04-2014 |
| 20150018531 | ANTI SEZ6 ANTIBODIES AND METHODS OF USE - Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided. | 01-15-2015 |
| 20150361165 | MFAP4 BINDING ANTIBODIES BLOCKING THE INTERACTION BETWEEN MFAP4 AND INTEGRIN RECEPTORS - Microfibrillar-associated protein 4 (MFAP4) binding antibodies are provided to prevent or to inhibit the proliferation of vascular smooth muscle cells and neointima formation in blood vessels. Furthermore, there are provided antibodies that effectively inhibit remodelling of vessels and prevent progression of arteriosclerosis as well as restenosis of vessels. The provided antibodies block the interaction between MF AP4 and integrin receptors. | 12-17-2015 |
| 530388210 | Binds nucleic acid or derivative or component thereof (e.g., DNA, RNA, DNA-RNA hybrid, nucleotide, nucleoside, carcinogen-DNA adduct, etc.) | 1 |
| 20120184719 | HYBRIDOMA PRODUCING ANTI-METHYLATED DNA ANTIBODY AND UTILIZATION OF SAME - The present invention relates to a hybridoma producing an anti-methylated DNA antibody, obtained by cell fusion of an antibody-producing cell obtained from an animal immunized with an antigen containing 5′-(5-methyl-2′-deoxycytidine-3′-phospho)-2′-deoxyguanosine 3′-phosphate with a myeloma cell. The present invention also relates to a monoclonal antibody produced by the hybridoma and a method for immunoprecipitation of a methylated DNA using the antibody. | 07-19-2012 |
| 530388220 | Binds receptor (e.g., transferrin receptor, Fc receptor, dihydropyridine receptor, IL-2 receptor, etc.) | 12 |
| 20110009602 | HUMAN CD28 SPECIFIC MONOCLONAL ANTIBODIES FOR ANTIGEN-NONSPECIFIC ACTIVATION OF T-LYMPHOCYTES - The invention teaches human-compatible monoclonal antibodies which are specific against human CD28 and human T-lymphocytes of several to all subgroups to activate without occupancy of an antigen receptor of the human T-lymphocytes and thus antigen-non-specifically. | 01-13-2011 |
| 20110178279 | DEVELOPMENT OF MASKED THERAPEUTIC ANTIBODIES TO LIMIT OFF-TARGET EFFECTS: APPLICATION TO ANTI-EGFR ANTIBODIES - In one embodiment, a masked monoclonal antibody (mAb) is provided, the mAb, encoded by a nucleic acid sequence or an amino acid sequence molecule comprising a signal sequence, a masking epitope sequence, a linker sequence that is cleavable by a protease specific to a target tissue; and an antibody or a functional fragment thereof. In another embodiment, a cross-masked mAb heterodimer complex is provided, comprising a first masked mAb, comprising a first signal sequence, a first masking epitope sequence, a first linker that is cleavable by a protease specific to a target tissue, and a first antibody or fragment thereof; and a second masked mAb, comprising a second signal sequence, a second masking epitope sequence, a second linker that is cleavable by a protease specific to a target tissue, and a second antibody or fragment thereof. | 07-21-2011 |
| 20120108797 | TARGETED BINDING AGENTS DIRECTED TO UPAR AND USES THEREOF - Targeted binding agents directed to the antigen uPAR and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the antigen uPAR. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementary determine regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies. | 05-03-2012 |
| 20120178912 | RECEPTOR ACTIVATOR OF NF-kappaB - Isolated receptors, DNAs encoding such receptors, and pharmaceutical compositions made therefrom, are disclosed. The isolated receptors can be used to regulate an immune response. The receptors are also useful in screening for inhibitors thereof. | 07-12-2012 |
| 20120253019 | NOVEL MONOCLONAL THYROID STIMULATING OR BLOCKING ANTIBODIES, PEPTIDE SEQUENCES CORRESPONDING TO THEIR VARIABLE REGIONS, AND THEIR USES IN DIAGNOSTIC, PREVENTIVE AND THERAPEUTIC MEDICINE - Monoclonal antibodies (mAbs) having thyroid stimulating activity (TSAb), especially full or considerably agonistic activity, or thyroid blocking activity (TBAb), which are obtainable by genetic immunization of mice, or fragments (F(ab′) | 10-04-2012 |
| 20130245236 | ANTIBODIES TO THE CHEMOKINE RECEPTOR XCR1 - The present invention relates to an antibody binding to murine XCR1. Furthermore, the present invention relates to a nucleic acid molecule encoding for said antibody, a vector comprising said nucleic acid molecule and a host cell comprising said vector. The present invention further embraces a method for producing the antibody. Moreover, the present invention claims the use of the antibody and a kit for detecting murine XCR1 | 09-19-2013 |
| 20140005368 | Low Fucose Cell Lines And Uses Thereof | 01-02-2014 |
| 20140031529 | MONOCLONAL ANTIBODY AND A METHOD THEREOF - The present invention relates to a humanized IgG1 isotype anti-CD6 antibody (T1h) that binds to the Scavenger receptor cysteine-rich (SRCR) domain 1 (D1) of CD6 present on the surface of thymic epithelial cells, monocytes, activated T cells and a variety of other cells types. | 01-30-2014 |
| 20140148584 | EPHB3-SPECIFIC ANTIBODY AND USES THEREOF - EphB3-specific antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating cancer. | 05-29-2014 |
| 20150376231 | PROTEIN PURIFICATION METHODS - A method for the purification of a desired protein from a protein preparation includes conditioning the protein preparation by treatment with soluble organic multivalent ions, immobilized organic multivalent ions, or both, optionally in the presence of supersaturated allantoin, thereby removing at least 90% of chromatin, then (1) precipitating the desired protein with a nonionic organic polymer in the presence of non-protein-precipitating salts at greater than physiological concentration to provide a precipitate of the desired protein; or (2) precipitating the desired protein with a nonionic organic polymer in the absence of non-precipitating salts at greater than physiological concentration to provide a precipitate and subsequently washing the precipitate with a nonionic organic polymer in the presence of non-protein-precipitating salts at greater than physiological concentration. | 12-31-2015 |
| 20160009762 | CHROMATOGRAPHIC PURIFICATION OF ANTIBODIES FROM CHROMATIN-DEFICIENT CELL CULTURE HARVESTS | 01-14-2016 |
| 20160176965 | CYTOTOXIC ANTI-LAG-3 MONOCLONAL ANTIBODY AND ITS USE IN THE TREATMENT OR PREVENTION OF ORGAN TRANSPLANT REJECTION AND AUTOIMMUNE DISEASE | 06-23-2016 |
| 530388230 | Binds lymphokine, cytokine, or other secreted growth regulatory factor, differentiation factor, or intercellular mediator specific for a hematopoietic cell (e.g., interleukin, interferon, erythropoietin, etc.) | 4 |
| 20090082550 | ANTIBODY COMPOSITIONS AND METHODS - Provided are concentrated preparations comprising single immunoglobulin variable domain polypeptides that bind target antigen with high affinity and are soluble at high concentration, without aggregation or precipitation, providing, for example, for increased storage stability and the ability to administer higher therapeutic doses. | 03-26-2009 |
| 20110130548 | ANTI-HUMAN IL-21 MONOCLONAL ANTIBODIES - Human anti-human IL-21 monoclonal antibodies and the hybridomas that produce them are presented. Certain of these antibodies have the ability to bind native human IL-21, a mutant recombinat IL-21 protein and/or peptide regions of human IL-21. These human anti-IL-21 antibodies are useful in therapeutic treatment of autoimmune and inflammatory diseases, particularly diseases mediated by T follicular helper cells, B cells T | 06-02-2011 |
| 20120157667 | Methods Of Producing Humanized Non-Human Mammals - Provided herein are methods of reconstituting functional human blood cell lineages in a non-human mammal comprising introducing human hematopoietic stem cells (HSCs) and nucleic acid encoding one or more human cytokines into an immunodeficient non-human mammal. The non-human mammal is maintained under conditions in which the nucleic acid is expressed and the human HSCs differentiate into functional human blood cell lineages in the non-human mammal, thereby reconstituting functional human blood cell lineages in the non-human mammal. Also provided are methods of producing human antibodies directed against an immunogen in a non-human mammal, hybridomas that secrete the monoclonal antibodies as well as antibodies (e.g., polyclonal antibodies; monoclonal antibodies) produced by the B cells and non-human mammals produced by the methods. | 06-21-2012 |
| 20130203970 | HEPATOCYTE GROWTH FACTOR (HGF) BINDING PROTEINS - The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors. | 08-08-2013 |
| 530388240 | Binds hormone or other secreted growth regulatory factor, differentiation factor, intercellular mediator, or neurotransmitter (e.g., insulin, human chorionic gonadotropin, intragonadal regulatory protein, Mullerian inhibiting substance, inhibin, epidermal growth factor, nerve growth factor, dopamine, norepinephrine, etc.) | 5 |
| 20110071278 | ANTIBODIES THAT RECOGNIZE CUTTING EDGE WITHIN THE TGF- BETA ACTIVATION CONTROLLING REGION - It is an object of the present invention to provide antibodies capable of detecting an active TGF-β generation reaction that is specific to pathogenesis, tissues, or isoforms. The present invention provides antibodies against an LAP fragment (or latent TGF-β) generated as a result of generation of active form of human TGF-β1, human TGF-β2 and human TGF-β3. The antibodies are able to specifically recognize respective cutting edges within protease cleavage sites existing in the region from the amino acid residue glycine at position 51 to the amino acid residue arginine at position 110 of human TGF-β1, and corresponding regions of human TGF-β2 and human TGF-β3. | 03-24-2011 |
| 20130018176 | METHODS OF PRODUCING HYBRIDOMAS AND MONOCLONAL ANTIBODIES AND ANTIBODIES PRODUCED THEREBY - Disclosed are a method of producing a hybridoma, a method of making an antibody involving the hybridoma, and an antibody made by the method. | 01-17-2013 |
| 20130131322 | ANTIBODY BEING CAPABLE OF BINDING TO TRANSFORMING GROWTH FACTOR ALPHA AND HAVING GROWTH-SUPPRESSING ACTIVITY ON CANCERS HAVING RAS GENE MUTATION - It has been found out that among antibodies showing reactivity with wild type TGF-α, antibodies less reactive with G79A-substituted TGF-α have an excellent growth-suppressing effect on cancer cells having a mutated Ras gene. Further, it has been found out that most of these antibodies have an activity of inhibiting EGFR tyrosine phosphorylation and/or an induction-suppressing activity on vascular endothelial cells. | 05-23-2013 |
| 20140288278 | CHROMATOGRAPHY PROCESS FOR RESOLVING HETEROGENEOUS ANTIBODY AGGREGATES - Disclosed are methods and processes utilizing multi-modal chromatography as a polishing step to separate heterogeneously charged (basic and acidic) aggregates and other impurities from partially a partially purified bulk product monoclonal antibody product. The resulting chromatographic process provides a scaleable production process that is cost effective and increases the productivity of the purification process over a platform utilizing a combination of anion and cation exchange chromatography to resolve heterogeneous aggregates. | 09-25-2014 |
| 20150025226 | MONOCLONAL ANTIBODY FOR ANALYZING HIGH-MOLECULAR WEIGHT ADIPONECTIN AND UTILIZATION OF SAME - A monoclonal antibody that does not show a crossreactivity with middle-molecular weight (MMW) adiponectin and specifically reacts with high-molecular weight (HMW) adiponectin alone is disclosed. The monoclonal antibody of the present invention can be produced by using HMW adiponectin as an antigen. According to the monoclonal antibody of the present invention, a convenient, high-accurate, and versatile reagent for analyzing HMW adiponectin can be provided. | 01-22-2015 |
| 530388250 | Binds plasma protein, serum protein, or fibrin (e.g., clotting factor, fibrinolytic factor, complement factor, immunoglobulin, apolipoprotein, etc.) | 1 |
| 20130253174 | MONOCLONAL ANTIBODY AGAINST SLIGHTLY OXIDIZED LOW-DENSITY LIPOPROTEIN AND HYBRIDOMA FOR PRODUCING THE SAME - Provided is a monoclonal antibody against slightly oxidized LDL, which can play a role as an important tool in the research and development of oxidized LDL. Also provided are a kit for the simple detection of slightly oxidized LDL and a method for the simple detection of slightly oxidized LDL from the biological sample of a subject to be tested which use the monoclonal antibody. By means of ELISA (Enzyme-Linked Immunosorbent Assay) using the monoclonal antibody as the solid phase antibody and an anti-apolipoprotein B antibody as the detection antibody, the degree of reaction between a severely oxidized low-density lipoprotein and the monoclonal antibody is low in comparison to the degree of reaction between a slightly oxidized low-density lipoprotein and the monoclonal antibody, and the monoclonal antibody specifically reacts with an oxidized low-density lipoprotein. | 09-26-2013 |
| 530388260 | Binds enzyme | 3 |
| 20110213129 | Diagnostics and treatments of periodontal disease - This invention relates to the PrtR-PrtK cell surface protein of | 09-01-2011 |
| 20130023654 | ANTIBODIES TO MATRIX METALLOPROTEINASE 9 - The present disclosure provides compositions and methods of use involving binding proteins, e.g., antibodies and antigen-binding fragments thereof, that bind to the matrix metalloproteinase-9 (MMP9) protein (MMP9 is also known as gelatinase-B), wherein the binding proteins comprise an immunoglobulin (Ig) heavy chain (or functional fragment thereof) and an Ig light chain (or functional fragment thereof). | 01-24-2013 |
| 20160083454 | CONTINUOUS MULTISTEP PROCESS FOR PURIFYING ANTIBODIES - The invention provides a three-step chromatography process for small and large-scale purification of proteins, specifically monoclonal antibodies, using only four buffer solutions made from a mother solution. | 03-24-2016 |
| 530388300 | Binds virus or component or product thereof (e.g., virus-associated antigen, etc.) | 3 |
| 20090312527 | Novel monoclonal antibodies against HPV proteins - Embodiments of the invention provide methods, monoclonal antibodies, polyclonal antibodies, assays, and kits for detecting HPV infection and HPV related cancer diagnosis, including infection by various HPV genotypes, early and/or late stage HPV-associated or HPV-specific cancers. Various monoclonal antibodies recognizing specific epitope for specific HPV protein or HPV type, common epitope for various HPV proteins or HPV types are obtained. These obtained monoclonal antibodies are useful tools in early clinical detection of HPV infection and general detection of HPV related diseases, specific detection of invasive cervical cancer, detection of other HPV related cancers, early stage precancerous lesions as well as late stage cancer progression. | 12-17-2009 |
| 20110301336 | ANTIBODY PRODUCED USING OSTRICH AND METHOD FOR PRODUCTION THEREOF - Disclosed is an antibody produced using an ostrich. Also disclosed is a method for producing the antibody. By using an ostrich, it becomes possible to produce antibodies (particularly antibodies for medical use), which have been hardly produced by using the mammals such as the mouse and the rat, homogeneously in a single body, in large quantities and in a simple manner. The method can overcome a disadvantage of lot-to-lot variation which may occur in the production of polyclonal antibodies using other animals. | 12-08-2011 |
| 20140275492 | HUMAN MONOCLONAL ANTIBODIES AND METHODS FOR PRODUCING THE SAME - The present invention provides for methods of producing human monoclonal antibodies against a wide variety of antigens including bacterial and viral antigens, as well as tumor antigens, and various autoantigens. Also provided are the antibodies themselves, nucleic acids encoding such antibodies, cells producing such antibodies, and methods of using such antibodies for diagnostic assays and passive immunity against disease states such as infection and cancer. | 09-18-2014 |
| 530388400 | Binds bacterium or similar microorganism or component or product thereof (e.g., Stretococcus, Legionella, Mycoplasma, bacterium-associated antigen, exotoxin, etc.) | 8 |
| 20080262204 | RECOMBINANT ANTIBODIES FOR THE DETECTION AND NEUTRALIZATION OF ANTHRAX TOXIN - A composition and method for treating a host having or at risk of infection by | 10-23-2008 |
| 20100016560 | Vaccine - The invention relates to a vaccine for the treatment of disease caused by | 01-21-2010 |
| 20110201786 | HYBRIDOMA PRODUCING ANTIBODIES TO LAWSONIA INTRACELLULARIS - The present invention relates to the field of animal health and in particular to | 08-18-2011 |
| 20110201787 | HYBRIDOMA PRODUCING ANTIBODIES TO LAWSONIA INTRACELLULARIS - The present invention relates to the field of animal health and in particular to | 08-18-2011 |
| 20110201788 | HYBRIDOMA PRODUCING ANTIBODIES TO LAWSONIA INTRACELLULARIS - The present invention relates to the field of animal health and in particular to | 08-18-2011 |
| 20110201789 | ANTIBODIES TO LAWSONIA INTRACELLULARIS - The present invention relates to the field of animal health and in particular to | 08-18-2011 |
| 20110201790 | HYBRIDOMA PRODUCING ANTIBODIES TO LAWSONIA INTRACELLULARIS - The present invention relates to the field of animal health and in particular to | 08-18-2011 |
| 20120208986 | USE OF MIXED MODE CHROMATOGRAPHY FOR THE CAPTURE AND PURIFICATION OF BASIC ANTIBODY PRODUCTS - Use of mixed mode chromatography for purification of an antibody from an antibody mixture, for example) a | 08-16-2012 |
| 530388700 | Binds hematopoietic cell or component or product thereof (e.g., erythrocyte granulocyte, macrophage, monocyte, platelet, myelogenous leukemia cell, bone marrow stem cell, granulocytic cell-surface antigen, hemoglobin, thrombospondin, glycophorin, etc.) | 1 |
| 530388730 | Binds lymphocytic or lymphocytic-like cell or component or product thereof (e.g., B cell, B-lineage bone marrow cell, null cell, natural killer cell, B-lymphoblastoid cell, B-lineage acute lymphoblastic leukemia cell, B-lymphocytic cell-surface antigen, etc.) | 1 |
| 20100234578 | ANTI-CD40 MONOCLONAL ANTIBODY - An antibody or a functional fragment thereof, acting agonistically or antagonistically on CD40. | 09-16-2010 |
| 530388800 | Binds cancer cell or component or product thereof (e.g., cell-surface antigen, etc.) | 5 |
| 20120136140 | ANTI-CADHERIN ANTIBODY - It is an object of the present invention to provide an anti-cadherin antibody having high antibody-dependent cellular cytotoxicity. The present invention provides an anti-cadherin antibody, which recognizes any one of an upstream region of EC1, a cadherin domain 4 (EC4) and a cadherin domain 5 (EC5), wherein an antibody-dependent cellular cytotoxicity at an antibody concentration of 1 μg/mL is 30% or more. | 05-31-2012 |
| 530388850 | Binds antigen characterized by name or molecular weight (e.g., CEA, NCA, CC glycoprotein, melanoma gp 150 antigen, etc.) | 4 |
| 20080214791 | MONOCLONAL ANTIBODIES TO HUMAN HIGH MOLECULAR WEIGHT-MELANOMA ASSOCIATED ANTIGEN - The present invention provides monoclonal antibodies that react against high molecular weight melanoma-associated antigen. These antibodies may be used for diagnostic and/or therapeutic purposes. | 09-04-2008 |
| 20140066604 | MOLECULAR MARKER CUEDC2 PROTEIN FOR PROGNOSTIC DETERMINATION OF BREAST CANCER ENDOCRINOLOGY THERAPY - Disclosed is a use of the CUEDC2 protein in the preparation of diagnostic agents for prognostic determination of the endocrinology therapy for the breast cancer patients and for the diagnosis of tumor such as breast cancer and ovarian cancer. The diagnostic agent comprises an antibody against the CUEDC2 protein, wherein the antibody is a monoclonal or polyclonal antibody against the CUEDC2 protein. Provided is a kit or a composition for prognostic determination of endocrinology therapy for the breast cancer patients and for the diagnosis of tumors such as breast cancer and ovarian cancer. The kit or composition comprises an antibody against the CUEDC2 protein. Further disclosed is a use of the CUEDC2 gene or protein in preparation of drugs for treating tumors, that is, small molecular substances and specific antibodies that specifically inhibit the expression or activity of the CUEDC2 gene\protein are used as a therapeutic agent to restore the sensitivity of drug-resistant tumors to drug treatment. The new use of the CUEDC2 protein provides a new basis for determining a dosage regimen of adjuvant therapy after surgical operation of the breast cancer patients, thereby improving the therapeutic effect of the anti-cancer drugs and alleviating the suffering and economic burden of the patients. | 03-06-2014 |
| 20140155583 | MONOCLONAL ANTIBODIES AND SINGLE CHAIN ANTIBODY FRAGMENTS AGAINST CELL-SURFACE PROSTATE SPECIFIC MEMBRANE ANTIGEN - Isolated monoclonal antibodies or an antigen binding portion thereof which bind to prostate specific membrane antigen in its native form occurring on the surface of tumor cells characterized in that it is linked to a label or a cytotoxic agent or constructed as a part of a bispecific antibody or a recombinant diabody. | 06-05-2014 |
| 20150368354 | METHODS FOR REDUCING AGGREGATE CONTENT IN PROTEIN PREPARATIONS - A method of reducing aggregate and product-contaminant complex content in a protein preparation including a desired protein includes (i) contacting the protein preparation with at least one solid surface comprising at least one surface-bound ligand capable of binding a metal, the surface-bound ligand being capable of binding a metal is initially substantially devoid of a metal, the operating conditions are selected to substantially prevent the binding of the desired protein to the at least one solid surface and (ii) separating the protein preparation from the surface-bound ligand, such that when more than one surface-bound ligand is present, each surface-bound ligand is independently either of the same net charge or charge neutral. | 12-24-2015 |
